588 related articles for article (PubMed ID: 28288821)
1. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
2. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
Chen F; Huang X; Wu M; Gou S; Hu W
Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
[TBL] [Abstract][Full Text] [Related]
3. Hybrid of DNA-targeting Chlorambucil with Pt(IV) Species to Reverse Drug Resistance.
Chen F; Xu G; Qin X; Jin X; Gou S
J Pharmacol Exp Ther; 2017 Nov; 363(2):221-239. PubMed ID: 28916659
[TBL] [Abstract][Full Text] [Related]
4. Novel platinum(IV) complexes conjugated with a wogonin derivative as multi-targeted anticancer agents.
Qin X; Xu G; Chen F; Fang L; Gou S
Bioorg Med Chem; 2017 Apr; 25(8):2507-2517. PubMed ID: 28314511
[TBL] [Abstract][Full Text] [Related]
5. Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative.
Wang X; Li L; Pei S; Zhu Q; Chen F
Pharmazie; 2020 Mar; 75(2):94-101. PubMed ID: 32213241
[TBL] [Abstract][Full Text] [Related]
6. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
[TBL] [Abstract][Full Text] [Related]
7. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
Wang M; Li G; Jiang G; Cai J; Liu Z; Huang R; Huang X; Wang H
J Med Chem; 2024 Apr; 67(8):6218-6237. PubMed ID: 38573870
[TBL] [Abstract][Full Text] [Related]
8. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway.
Xu X; Zhang Y; Li W; Miao H; Zhang H; Zhou Y; Li Z; You Q; Zhao L; Guo Q
Biochem Pharmacol; 2014 Nov; 92(2):220-34. PubMed ID: 25264278
[TBL] [Abstract][Full Text] [Related]
9. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance.
Chen F; Pei S; Wang X; Zhu Q; Gou S
Biochem Biophys Res Commun; 2020 Jan; 521(3):753-761. PubMed ID: 31703842
[TBL] [Abstract][Full Text] [Related]
10. Wogonin inhibits H2O2-induced angiogenesis via suppressing PI3K/Akt/NF-κB signaling pathway.
Zhou M; Song X; Huang Y; Wei L; Li Z; You Q; Guo Q; Lu N
Vascul Pharmacol; 2014 Mar; 60(3):110-9. PubMed ID: 24534483
[TBL] [Abstract][Full Text] [Related]
11. DN604: A platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells.
Chen F; Jin X; Zhao J; Gou S
Exp Cell Res; 2018 Mar; 364(1):68-83. PubMed ID: 29397071
[TBL] [Abstract][Full Text] [Related]
12. Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways.
Chen Y; Li H; Li M; Niu S; Wang J; Shao H; Li T; Wang H
J Ethnopharmacol; 2017 Mar; 200():165-173. PubMed ID: 28232127
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
14. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
15. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
[TBL] [Abstract][Full Text] [Related]
16. Alternation of adriamycin penetration kinetics in MCF-7 cells from 2D to 3D culture based on P-gp expression through the Chk2/p53/NF-κB pathway.
Lu M; Zhou F; Hao K; Liu J; Chen Q; Ni P; Zhou H; Wang G; Zhang J
Biochem Pharmacol; 2015 Jan; 93(2):210-20. PubMed ID: 25478729
[TBL] [Abstract][Full Text] [Related]
17. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
18. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
19. Beclin1 affected by DN604 upregulates chemo-sensitivity of cervix SiHa cancer cells via inhibiting CK2-MRN-DSBs repair.
Chen F; Sun S; Liu N; Pei S; Zhu Q; Wang X; Gou S
Anticancer Drugs; 2019 Sep; 30(8):774-783. PubMed ID: 31274516
[TBL] [Abstract][Full Text] [Related]
20. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
Kim EH; Jang H; Shin D; Baek SH; Roh JL
Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
